SATB2 and endometrial serous adenocarcinoma: This contrasts with the results of another study [9], which found SATB2 expression in 8/19 (42%) uterine carcinosarcomas (inside the sarcomatous portion), 10/26 (38%) grade 3 endometrial endometrioid carcinomas, 11/30 (37%) undifferentiated/dedifferentiated endometrial carcinomas, and 6/22 (27%) uterine serous carcinomas, while none of the 15 clear cell carcinomas were SATB2 positive.